Real-world outcomes with DVRd for NDMM

Results from a retrospective study, evaluating real-world outcomes in patients with newly diagnosed multiple myeloma (NDMM) treated with first-line daratumumab + bortezomib + lenalidomide + dexamethasone (DVRd; N = 464), were reported in Haematologica by Parrondo et al.

Key data: Among patients who underwent autologous hematopoietic stem cell transplantation (auto-HSCT; n = 315), the overall response rate (ORR) to induction was 98%, with 3-year progression-free survival (PFS) and overall survival (OS) rates of 85% and 96%, respectively; measurable residual disease (MRD) negativity at any time was associated with longer PFS (median, not reached vs 53 months; p < 0.001). Among patients who did not undergo auto-HSCT (n = 149), the ORR was 87%, with 3‑year PFS and OS rates of 60% and 85%, respectively. In the overall cohort, once-weekly bortezomib demonstrated comparable ORR and MRD negativity rates vs twice-weekly dosing. In total, 79 patients relapsed following first-line DVRd. 

Key learning: DVRd demonstrated effectiveness in the real-world setting as a first-line treatment for patients with NDMM, regardless of whether it was used with or without auto-HSCT.